Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

被引：16

作者：

Brozos-Vazquez, Elena ^{[1
]}

Toledano-Fonseca, Marta ^{[2
,3
]}

Costa-Fraga, Nicolas ^{[4
,5
,6
,7
]}

Garcia-Ortiz, Maria Victoria ^{[2
]}

Diaz-Lagares, Angel ^{[4
,5
,6
,8
]}

Rodriguez-Ariza, Antonio ^{[2
,3
,9
]}

Aranda, Enrique ^{[2
,3
,12
]}

Lopez-Lopez, Rafael ^{[5
,6
,10
,11
,13
]}

机构：

[1] Univ Hosp A Coruna CHUAC, Med Oncol Dept, La Coruna, Spain

[2] Canc Network Biomed Res Ctr CIBERONC, Madrid, Spain

[3] Americio, 17 Portal E 2C, Madrid 28021, Spain

[4] Epigen Unit, Canc Epigen, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain

[5] CIBERONC, Clin Univ Hosp, Santiago De Compostela, Spain

[6] CIBERONC, Hlth Res Inst Santiago De Compostela, Santiago De Compostela, Spain

[7] Univ Santiago De Compostela, Santiago De Compostela, Spain

[8] Univ Hosp Complex Santiago De Compostela CHUS, Dept Clin Anal, Santiago De Compostela, Spain

[9] Reina Sofia Univ Hosp, Med Oncol Dept, Cordoba, Spain

[10] Med Oncol Dept, Santiago De Compostela, Spain

[11] Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain

[12] Univ Cordoba, Fac Med, Dept Med, Cordoba, Spain

[13] Santiago De Compostela Sch Med, Oncol, Santiago De Compostela, Spain

来源：

CANCER TREATMENT REVIEWS | 2024年 / 125卷

关键词：

Pancreatic adenocarcinoma; Potential therapeutic biomarkers; Agnostic therapy; MSI-H; TMB; TUMOR MUTATIONAL BURDEN; SOLID TUMORS; DUCTAL ADENOCARCINOMA; GEMCITABINE; SURVIVAL; LAROTRECTINIB; MULTICENTER; FOLFIRINOX; THERAPIES; ADULTS;

D O I：

10.1016/j.ctrv.2024.102719

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15-20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted therapies in pancreatic cancer is increasingly feasible due to tumor-agnostic treatments, such as PARP inhibitors in patients with BRCA1, BRCA2 or PALB2 alterations or immunotherapies in patients with high microsatellite instability/tumor mutational burden. In addition, other therapeutic molecules have been developed for patients with KRAS G12C mutation or fusions in NTRK or NRG1. Consequently, there has been a growing interest in biomarkers that may help guide targeted therapy in pancreatic cancer. Therefore, this review aims to offer an updated perspective on biomarkers with therapeutic potential in pancreatic cancer.

引用

页数：7

共 85 条

[1] Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation [J].

Bekaii-Saab, Tanios S. ;

Yaeger, Rona ;

Spira, Alexander I. ;

Pelster, Meredith S. ;

Sabari, Joshua K. ;

Hafez, Navid ;

Barve, Minal ;

Velastegui, Karen ;

Yan, Xiaohong ;

Shetty, Aditya ;

Der-Torossian, Hirak ;

Pant, Shubham .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) :4097-+

[2] Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies [J].

Bhamidipati, Deepak ;

Subbiah, Vivek .

TRENDS IN CANCER, 2023, 9 (03) :237-249

[3] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[4]

Carrizosa DR, 2022, J CLIN ONCOL, V40

[5] Clinical and genomic characterisation of early-onset pancreatic cancer [J].

Castet, Florian ;

Fabregat-Franco, Carles ;

Castillo, Gloria ;

Navarro, Victor ;

Sierra, Alexandre ;

Acosta, Daniel Alejandro ;

Lopez-Valbuena, Daniel ;

Dienstmann, Rodrigo ;

Tabernero, Josep ;

Vivancos, Ana ;

Tian, Tian, V ;

Macarulla, Teresa .

EUROPEAN JOURNAL OF CANCER, 2023, 194

[6]

Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8

[7] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

[8] Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer A Randomized Clinical Trial [J].

Conroy, Thierry ;

Castan, Florence ;

Lopez, Anthony ;

Turpin, Anthony ;

Ben Abdelghani, Meher ;

Wei, Alice C. ;

Mitry, Emmanuel ;

Biagi, James J. ;

Evesque, Ludovic ;

Artru, Pascal ;

Lecomte, Thierry ;

Assenat, Eric ;

Bauguion, Lucile ;

Ychou, Marc ;

Bouche, Olivier ;

Monard, Laure ;

Lambert, Aurelien ;

Hammel, Pascal .

JAMA ONCOLOGY, 2022, 8 (11) :1571-1578

[9] Current standards and new innovative approaches for treatment of pancreatic cancer [J].

Conroy, Thierry ;

Bachet, Jean-Baptiste ;

Ayav, Ahmet ;

Huguet, Florence ;

Lambert, Aurelien ;

Caramella, Caroline ;

Marechal, Raphael ;

Van Laethem, Jean-Luc ;

Ducreux, Michel .

EUROPEAN JOURNAL OF CANCER, 2016, 57 :10-22

[10] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

← 1 2 3 4 5 6 7 8 9 →